

PhilHealth Advisory



No. 10-04-2012

Confinements due to Corona Virus and Chikungunya are compensable

In connection with the recent news that may affect the health of the Filipinos regarding Chikungunya, a viral disease caused by mosquito and the discovery of what is believed to be a new type of corona virus tentatively referred to as Novel Corona virus 2012, PhilHealth would like to reiterate the following:

- Confinements due to the following illnesses are covered by PhilHealth
- Both diseases fall under case Type A
- When treated in a Level 3 or 4 facility, members are entitled to the following benefits under the fee-for-service payment : P500/day for room and board and maximum of P4,200 for drugs and medicines, P3,200 for x-ray, laboratory and others and P2,000 for professional fee. Chikungunya may also be treated in level 1 or 2 facility but with lower benefits.
- Availment of these benefits is subject to medical evaluation and existing policies on claims payment. Employed and Individually paying members (IPMs) should have at least three months' premium contributions within a six-month period prior to the month of availment to be able to avail of these benefits. On the other hand, sponsored and overseas worker-members may avail themselves of the benefits within the validity period of their PhilHealth coverage as reflected in their PhilHealth cards and enhanced Member Data Records (MDRs) respectively.

According to the World Health Organization (WHO), Chikungunya causes fever and severe joint pain and shares some clinical signs with dengue and can be misdiagnosed in areas where dengue is common. Other symptoms include muscle pain, headache, nausea, fatigue and rash. There is no specific drug to cure the disease and there is no commercial vaccine for this.

Coronaviruses, on the other hand, are a large family of viruses that includes viruses that may cause a range of illnesses in humans, from the common cold to SARS. In September 2012, the United Kingdom informed WHO of a case of a 49 year old Qatari national with travel history to Saudi Arabia and Qatar of acute respiratory syndrome. WHO has continued to monitor the situation and no additional confirmed cases have been reported and there is no evidence so far of person to person transmission of the novel coronavirus to date.


DR. EDUARDO P. BANZON
President and CEO